Premium
Cyclosporin A and FK‐506 in inhibition of rat ito cell activation in vitro
Author(s) -
Ikeda Hitoshi,
Fujiwara Kenji
Publication year - 1995
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840210440
Subject(s) - in vivo , in vitro , cell growth , dna synthesis , cell culture , hepatic stellate cell , microbiology and biotechnology , pharmacology , chemistry , biology , biochemistry , endocrinology , genetics
Ito cells are the primary matrix‐producing cells in the liver. In hepatic fibrosis in vivo or culture on plastic, these cells undergo activation, a process characterized by cell proliferation, fibrogenesis, and smooth muscle α‐actin expression. The cytosolic‐binding proteins of cyclosporin A (CsA) and FK506 accelerate folding of various proteins including collagen and become inactivated by binding to those agents. CsA is shown to inhibit collagen synthesis in cultured fibroblasts. These findings prompted us to examine the effect of cyclosporin A and FK506 on Ito cell activation. CsA and FK506 reduced DNA synthesis in a dose‐related manner, to 26% and 45% of controls at 5 μmol/L, respectively, without affecting total protein synthesis. CsA reduced collagen synthesis in a dose‐related manner, to 70% of controls at 5 μmol/L without affecting noncollagenous protein synthesis, whereas FK506 changed neither collagen synthesis nor noncollagenous protein synthesis. Moreover, smooth muscle α‐actin expression was reduced by 0.5 μmol/L CsA, but not by FK506. CsA merits consideration for the therapy of hepatic fibrosis. FK506 may also be a candidate for such therapy through inhibitory action on Ito cell proliferation. (H EPATOLOGY 1995; 21:1161–1166.)